Anti Tnf Medications
Anti Tnf Medications - Related Videos
16:07
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
0 Views •
Cited by 1 •
2017
A protocol for the determination of the relative anti-apoptotic activity of an anti-TNFα mAb using a neutralization mechanism with WEHI 164 cells is presented here. This protocol is useful for comparing the neutralization strength of different molecules with the same biological functionality.
01:24
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
0 Views •
2024
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
06:59
A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
0 Views •
Cited by 5 •
2016
This study presents a novel device that offers an easy route to quickly provide medications and fluids in patients with limited or difficult IV access. This small-diameter device is placed in the distal third of the rectum, allowing for ongoing medication and fluids administration.
10:15
Isolation and Characterization of Neutrophils with Anti-Tumor Properties
0 Views •
Cited by 46 •
2015
Neutrophils play an important role not only in host defense against invading microorganisms, but are also involved in the immune surveillance of tumor cells. Here, we describe techniques related to the isolation of neutrophils with anti-tumor properties and methods for monitoring anti-tumor neutrophil function in vitro and in vivo.
10:55
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
0 Views •
2025
We provide a step-by-step immunocytochemistry (ICC) methodology for detecting anti-MDA5. This approach involves cell fixation, permeabilization, antibody incubation, and imaging techniques, which allow for the accurate detection of anti-MDA5 autoantibodies, aiding in the diagnosis of rapidly progressing interstitial lung disease in myositis patients.
FAQs
Anti-TNF medications can reduce signaling either by binding TNF directly or by preventing TNF from activating its cell-surface receptors. These mechanisms interrupt the communication that normally promotes downstream inflammatory signaling and immune-cell recruitment. Understanding this distinction helps explain how the therapies limit inflammation at an early signaling step rather than only treating its later symptoms.
TNF contributes to immune responses that can drive persistent inflammation and tissue damage. When its activity is reduced, downstream inflammatory signaling and recruitment of immune cells are also limited. This can decrease excessive inflammatory activity in affected tissues, helping control symptoms while supporting protection of tissues from ongoing immune-mediated injury.
TNF participates in immune responses, so reducing its activity can influence normal immune function as well as harmful inflammation. For this reason, clinical use requires careful monitoring for infections and other adverse events. This safety consideration is central to balancing the benefits of inflammation control against the potential consequences of altering immune signaling.
Clinical applications include rheumatoid arthritis, inflammatory bowel disease, psoriasis, and other immune-mediated disorders. These conditions differ in their affected tissues and clinical manifestations, but each can involve excessive inflammation that contributes to symptoms or tissue injury. Anti-TNF therapy provides an option for controlling that inflammatory activity when treatment is clinically appropriate.
Anti-TNF therapy may be considered when conventional treatments are insufficient to control an immune-mediated disorder. Its role is therefore not simply to provide another anti-inflammatory option, but to address persistent or inadequately controlled disease through targeted interference with TNF-related signaling. Clinical use also includes attention to infection risk and other adverse events.
The intended outcomes include relief of symptoms, protection of affected tissues, and improved long-term disease management. These benefits result from reducing excessive inflammatory activity rather than merely masking symptoms. Because the same pathway is connected to immune responses, treatment outcomes must be considered alongside continued monitoring for infections and other adverse events.